abbvie logo

AbbVie Gets U.S. FDA Priority Review for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for Treating Chronic Hepatitis C

Feb 02, 2017 AbbVie, a global biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P), being evaluated for treating all major genotypes (GT1-6) of chronic hepatitis C virus (HCV). The FDA grants priority review … Continue reading AbbVie Gets U.S. FDA Priority Review for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for Treating Chronic Hepatitis C

Advertisements
abbvie logo

AbbVie Announces Four New Global Research Collaborations

Jan 09, 2017 AbbVie, a global biopharmaceutical company, has announced four new collaborations and investments with leading healthcare innovators for advancing early-stage research in key therapeutic areas such as immunology and oncology. The company is committed to investing in and developing transformational science and technologies to advance the next-generation of therapies across its robust pipeline … Continue reading AbbVie Announces Four New Global Research Collaborations

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – November 2016

New Research Details Published by Merck Scientists About the Early Development of Verubecestat November 2, 2016 Merck has announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat. It is an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is used … Continue reading Top Pharma News – November 2016

abbvie logo

U.S. Food and Drug Administration Gives AbbVie the Orphan Drug Designation for Investigational IL-23 Inhibitor Risankizumab for Treating Pediatric Patients with Crohn’s Disease

Nov 30, 2016 AbbVie, a global biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to risankizumab (ABBV-066; formerly BI 655066) for the investigational treatment of pediatric patients with Crohn's disease. It is a special type of inflammatory bowel disease which commonly involves the end of the … Continue reading U.S. Food and Drug Administration Gives AbbVie the Orphan Drug Designation for Investigational IL-23 Inhibitor Risankizumab for Treating Pediatric Patients with Crohn’s Disease

abbvie logo

Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) from AbbVie Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease

Nov 15, 2016 AbbVie (NYSE: ABBV), a global biopharmaceutical company has announced that 98 percent (n=102/104) of chronic hepatitis C virus (HCV) infected patients with severe chronic kidney disease (CKD) achieved sustained virologic response following 12 weeks of treatment (SVR12) with its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) in the primary intent-to-treat (ITT) … Continue reading Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) from AbbVie Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease

World's 12 Most Reputable Pharmaceutical

The World’s Most Reputable Pharmaceutical Companies 2016

Customers’ satisfaction is immensely important for the pharmaceutical companies. When these companies focus on innovation and act responsibly, they gain the required trust from the customers all over the world. Based on how good people feel about big pharma, a ranking has been published by the Reputation Institute (RI). Based on the ranking, we have … Continue reading The World’s Most Reputable Pharmaceutical Companies 2016

Biosimilars

Biosimilar Products and Its Commercial Potential

The increasing demand for medicines and other biologic products paved the way to the development of methods that can speed up its production in order to meet the needs of its consumers. One of which is the utilization of biosimilar product, which is defined by the U.S. Food and Drug Administration (FDA) as ‘a biological … Continue reading Biosimilar Products and Its Commercial Potential

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma Oncology | Top News – Fall 2016

AbbVie and Bristol-Myers Squibb Collaborate to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen July 25, 2016 AbbVie and Bristol-Myers Squibb Company have announced a clinical trial collaboration for evaluating the safety, efficacy, and tolerability of investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) of AbbVie in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen … Continue reading Pharma Oncology | Top News – Fall 2016

abbvie-bristol

AbbVie and Bristol-Myers Squibb Collaborate to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen

July 25, 2016 AbbVie and Bristol-Myers Squibb Company have announced a clinical trial collaboration for evaluating the safety, efficacy, and tolerability of investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) of AbbVie in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen of Bristol-Myers Squibb as a treatment for relapsed extensive-stage small cell lung cancer (SCLC). “We believe the combination … Continue reading AbbVie and Bristol-Myers Squibb Collaborate to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen

Biogen-Abbvie

European Union Approves Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (daclizumab) for the Treatment of Multiple Sclerosis

Jul 05, 2016 Biogen and AbbVie have announced that the European Commission (EC) has granted marketing authorization for ZINBRYTA™ (daclizumab) for treating adult patients with relapsing forms of multiple sclerosis (RMS). ZINBRYTA is a once-monthly, subcutaneous, self-administered injection. Professor Gavin Giovannoni, Chair of Neurology, Blizard Institute, Barts and The London School of Medicine and Dentistry, said: “Clinical … Continue reading European Union Approves Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (daclizumab) for the Treatment of Multiple Sclerosis